3960 Broadway
New York, NY 10032

Tel:    646-218-1850
Fax:   212-740-2570

About Forticell Bioscience, Inc.


About the Company

Mission Statement

Management Team

Board of Directors

Location & Directions


Investor Relations

Whats New


Press Release

For Immediate Release


NEW YORK, NY - December 5, 2007 -- Ortec International, Inc. (OTCBB: OTCI), a company focused on advancing regenerative medicine through the development of cellular technology and advanced biomaterial products, announced today that its Chief Executive Officer and President, Dr. Costa Papastephanou, is scheduled to present at the New York Society of Security Analysts 11th Annual Biotech/Specialty Pharma Conference to be held from December 11-12, 2007, in New York City. The presentation by Dr. Papastephanou is scheduled for Thursday, December 12, at 3:30 PM Eastern.

Recently, Ortec International announced that it had submitted a Pre-Market Approval application to the Food and Drug Administration for the use of OrCel®, a bilayered cellular matrix of engineered tissue to heal chronic and acute wounds, in the treatment of Venous Leg Ulcers (VLU). These ulcers are the most frequently occurring types of hard to heal wounds and are responsible for the loss of 2 million workdays per year in the U.S. alone and entail overall treatment costs estimated at $2.5 to $3.5 billion annually. The data from the Phase III Clinical Trial showed a significant improvement in wound healing in the OrCel® treated patients.

A total of 20 publicly traded companies are expected to present at the New York Society of Security Analysts 11th Annual Biotech/Specialty Pharma Conference. In addition, key note speeches will be given by investment professionals specializing in life science companies. Ortec International, presenting on the second day of the event, is positioned among several other leading companies with advanced or commercial stage medical products and pharmaceuticals addressing a variety of novel cell therapies and regenerative applications.

About the NYSSA
Since 1937, the New York Society of Security Analysts (NYSSA) has educated and informed investment professionals, providing them with a vibrant forum for the exchange of ideas and information. NYSSA was founded by a group that included Benjamin Graham, the "father of securities analysis" and one of the most influential men in the history of finance.

NYSSA promotes awareness and understanding of securities analysis, investing, and the operation of the securities markets. Our members are recognized as ethical, knowledgeable members of the investment decision-making community. With more than 9,000 members, NYSSA is the largest of the more than 134 financial analyst societies worldwide that comprise the CFA Institute.

About Ortec International, Inc.
Ortec International, Inc. (OTCI.PK) is a company focused on advancing regenerative medicine and stem cell therapy through the development and commercialization of innovative products by combining advanced cell technology and advanced biomaterials. Ortec's lead product is OrCel® (Bilayered Cellular Matrix). Ortec's current focus is the application of OrCel® to heal chronic and acute wounds. OrCel® is composed of a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair.

A pivotal clinical trial evaluating a cryopreserved version of OrCel® in the treatment of venous leg ulcers has been completed and a Pre Market Approval (PMA) application has been filed. Ortec has completed a confirmatory trial requested by the FDA, and the data from this trial are expected to be integrated with the results of the pivotal clinical trial and submitted as a clinical supplement to its PMA filing. Ortec has already obtained FDA approvals for use of a non-frozen version of OrCel® in the treatment of Epidermolysis Bullosa and donor sites in burn patients. In addition, the FDA has granted Ortec approval to initiate a pivotal (Phase III) trial evaluating OrCel® for the treatment of diabetic foot ulcers.

Ortec recently acquired two fibrin derived advanced biomaterial technologies, Fibrin MB and HaptidesT. Fibrin MB has the potential to play a significant role in advancing stem cell therapy having demonstrated the ability to efficiently recover adult stem cells and allow for their growth, differentiation and potential re-implantation into the patient. HaptidesT utilize proprietary synthetic peptides that mimic the mechanism of cell attachment to fibrin. These peptides have demonstrated the ability to significantly enhance cell attraction and attachment providing the potential to use HaptidesT in the development of product opportunities applicable to the cosmetic tissue augmentation, wound healing, orthopedics and drug delivery markets.

This news release may contain "forward-looking statements" for the purposes of the United States Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3B-6 under The Exchange Act. Without limitation, statements regarding expected FDA approvals, clinical trial results, product performance, expectations with respect to sales, gross margins, research and development expenditures, earnings per share, capital expenditures, collaborations, or other expansion opportunities would be “forward-looking statements.” These statements may be identified by words such as "expects", "anticipates", "intends", "estimates", "believes" or similar expressions in connection with any discussion of future financial and operating performance. The forward-looking statements contained herein involve risks and uncertainties that may cause results to differ materially from the Company's expectations including but not limited to, global economic trends, competitive pricing or product developments, government legislation and/or regulations, technology, manufacturing, legal and patent issues, suppliers, capital availability, personnel changes, cancellation or delays in renewal of contracts, and lack of suitable raw materials or packaging materials. Investors are cautioned to review risk factors in the Company's filings with the United States Securities and Exchange Commission.


At the Company: [email protected]

Ortec's Investor Relations Firm: Jordan Darrow at [email protected] or 631-367-1866

   Home   |   About Us   |   Product & Technology   |   Investor Relations   |   Contact   |   Site Map